Telomir Financial Statements From 2010 to 2025

TELO Stock   1.40  0.03  2.10%   
Telomir Pharmaceuticals,'s financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Telomir Pharmaceuticals,'s valuation are provided below:
Market Capitalization
49.2 M
Earnings Share
(0.37)
We have found sixty-seven available fundamental trend indicators for Telomir Pharmaceuticals, Common, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Telomir Pharmaceuticals,'s current fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road.
Check Telomir Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telomir Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 14.8 M, Selling General Administrative of 11.6 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 199. Telomir financial statements analysis is a perfect complement when working with Telomir Pharmaceuticals, Valuation or Volatility modules.
  
Build AI portfolio with Telomir Stock
Check out the analysis of Telomir Pharmaceuticals, Correlation against competitors.

Telomir Pharmaceuticals, Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.7 M1.5 M623.7 K
Slightly volatile
Short and Long Term Debt Total79.9 K84.1 K140.8 K
Very volatile
Total Current Liabilities863.7 K783.1 K385.5 K
Slightly volatile
Accounts Payable472.4 K675.7 K190.8 K
Slightly volatile
Common Stock Shares Outstanding23.7 M26.6 M29 M
Slightly volatile
Liabilities And Stockholders Equity1.7 M1.5 M623.7 K
Slightly volatile
Other Stockholder Equity37.7 M35.9 M7.7 M
Slightly volatile
Total Liabilities863.7 K783.1 K385.5 K
Slightly volatile
Short Term Debt79.9 K84.1 K140.8 K
Very volatile
Non Currrent Assets Other5.2 MM1.2 M
Slightly volatile
Cash And Short Term Investments1.5 M1.5 M266.8 K
Slightly volatile
Other Current Assets63.2 K66.6 K66.2 K
Slightly volatile
Net Receivables104 K117 K127.6 K
Slightly volatile
Inventory242.6 K273 K297.6 K
Slightly volatile
Short and Long Term Debt80.8 K90.9 K99.1 K
Slightly volatile

Telomir Pharmaceuticals, Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General Administrative11.6 M11.1 M2.1 M
Slightly volatile
Other Operating Expenses14.8 M14.1 MM
Slightly volatile
Research Development1.3 M2.6 M619.8 K
Slightly volatile
Total Operating Expenses14.8 M14.1 MM
Slightly volatile
Cost Of Revenue3.2 M3.5 M3.9 M
Slightly volatile

Telomir Pharmaceuticals, Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Change In Working Capital177.2 K145.4 K72.2 K
Slightly volatile
Total Cash From Financing Activities7.6 M7.3 M1.7 M
Slightly volatile
Depreciation3.3 MM2.1 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables517.9 K582.6 K635.2 K
Slightly volatile
Cash Per Share0.0450.04290.0055
Slightly volatile
Income Quality0.550.30670.7546
Slightly volatile
Current Ratio2.041.94430.3095
Slightly volatile
Debt To Assets0.0670.07069.7103
Slightly volatile
Ebt Per Ebit2.561.35053.1459
Slightly volatile
Quick Ratio2.041.94430.3095
Slightly volatile
Cash Ratio1.951.85930.2393
Slightly volatile
Debt Ratio0.0670.07069.7103
Slightly volatile

Telomir Pharmaceuticals, Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap97.4 M109.5 M119.4 M
Slightly volatile
Enterprise Value96.4 M108.5 M118.3 M
Slightly volatile

Telomir Fundamental Market Drivers

About Telomir Pharmaceuticals, Financial Statements

Telomir Pharmaceuticals, investors utilize fundamental indicators, such as revenue or net income, to predict how Telomir Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-523.6 K-549.8 K
Cost Of Revenue3.5 M3.2 M

Pair Trading with Telomir Pharmaceuticals,

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.

Moving together with Telomir Stock

  0.62NVO Novo Nordisk AS Buyout TrendPairCorr

Moving against Telomir Stock

  0.66TLK Telkom Indonesia TbkPairCorr
  0.58KB KB Financial GroupPairCorr
  0.58EC Ecopetrol SA ADRPairCorr
  0.57MTC MMTEC Inc Tech BoostPairCorr
  0.54SHG Shinhan FinancialPairCorr
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Telomir Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telomir Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telomir Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telomir Pharmaceuticals, Common Stock:
Check out the analysis of Telomir Pharmaceuticals, Correlation against competitors.
You can also try the AI Portfolio Prophet module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Return On Assets
(1.67)
Return On Equity
(3.03)
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.